a cold reading of the literature
PT-141 is bremelanotide — a melanocortin agonist approved for exactly one thing, read here in cold light.
Approved for low sexual desire in premenopausal women. Everything else — men, erections, performance — is off-label. The warnings come first.
The short version
PT-141 is the research name for bremelanotide. It is a small synthetic peptide that acts on switches in the brain — melanocortin receptors — that influence sexual desire. The FDA approved it in June 2019 for one narrow use: acquired, generalized HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes real personal distress) in women before menopause. Every other use you may have read about — in men, for erections, for "performance" — is off-label and still investigational. The effect in the approved group is real but modest, and the drug carries a blood-pressure warning. This site reads the published record plainly, and cites it.
What PT-141 is
Compound: PT-141. International name: bremelanotide. Class: melanocortin (MC3R/MC4R) receptor agonist [11]. It is a synthetic analogue of alpha-MSH (alpha-melanocyte-stimulating hormone — a natural brain peptide, cleaved from the precursor pro-opiomelanocortin, that activates these same receptors), built as a seven-amino-acid ring [1].
The approval is the spine of the whole story. Bremelanotide injection was approved June 21, 2019 under NDA 210557 for acquired, generalized HSDD in premenopausal women [11]. That is the only indication. "Acquired" means the low desire developed after a period of normal function; "generalized" means it is not limited to a specific partner or situation. The molecule has been studied in men with erectile dysfunction since the early 2000s [6][7], but that work never reached approval and is described on this site strictly as off-label and early-phase.
The approval also did not arrive cleanly. Development ran across more than a decade, the route shifted from intranasal to subcutaneous, and the magnitude of benefit has been contested in the published literature [13][15]. We report the approval and the dispute together, because both are in the record.
The mechanism is central, not vascular. PT-141 acts on the brain's desire circuitry. It is not a PDE-5 inhibitor (the class that improves erectile blood flow at the periphery), and it does not raise testosterone or act through the hypothalamic-pituitary-gonadal axis [12]. Read how PT-141 works in the brain for the receptor detail.
PT-141 peptide: structure and identity
The PT-141 peptide is a cyclic heptapeptide — seven amino acids joined in a ring — with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH [1]. Molecular weight is 1025.2 Da; formula C50H68N14O10; CAS 189691-06-3 [1]. A lactam bridge between two side chains closes the ring, and that cyclic structure makes it more stable than linear melanocortin peptides [1].
Structurally it is a close relative of an older melanocortin peptide, but with the C-terminal amide swapped for a carboxylic acid [1]. That single change shifts the pharmacology toward the sexual-desire effect rather than the tanning effect, though pigment effects survive at the skin (see PT-141 side effects).
PT-141 as a melanocortin (MC3R/MC4R) receptor agonist
PT-141 is a melanocortin receptor agonist. Its main target is the melanocortin 4 receptor (MC4R), with secondary activity at MC3R [1][5]. These are central-nervous-system receptors — brain switches — concentrated in the hypothalamus and limbic system [11]. They belong to a five-member family (MC1R through MC5R); MC3R and MC4R are the two that matter for desire, while MC1R sits in the skin and is the reason repeated dosing can darken pigment.
MC4R is the reason the drug works on desire, and also the reason it is not selective for sex alone. The same receptor sits in appetite circuits, which is why high-frequency dosing in early metabolic studies changed food intake and body weight [12]. The desire effect and the appetite effect run through the same switch — a single receptor doing more than one job, which is part of why the approved label caps how often the drug can be used [11].
Who it is for — and who it is not
The approved population is narrow on purpose. Bremelanotide is approved for premenopausal women with acquired, generalized HSDD — and for no one else [11]. It is not approved for men, for postmenopausal women, for erectile dysfunction, or for sexual "performance" or enhancement of any kind [11][12].
The male research exists, and it is genuinely interesting, but it is a separate and unfinished story. Early-phase studies in men with erectile dysfunction tested intranasal and subcutaneous PT-141 and reported dose-dependent erectile activity [6][7]. That evidence is early-phase and investigational; it never became an approval, and we never describe it as established. The distinction between the approved women's indication and the off-label male research runs through every page here.
What the record actually shows
Efficacy in the approved group is real and modest. In two identical Phase 3 trials (RECONNECT, n=1267 premenopausal women with HSDD), bremelanotide 1.75 mg subcutaneous as-needed raised desire (integrated FSFI-desire +0.35, P<.001) and cut desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo over 24 weeks [3]. FSFI and FSDS are the standard questionnaires trials use to score sexual desire and the distress that low desire causes. Both coprimary endpoints were met. A 52-week extension found no new safety signals and sustained the effect [4].
The caveats are not footnotes. Nausea reached 40.4% in long-term use and was the principal reason participants discontinued [4]. Flushing (20.6%) and headache (12.0%) followed [4]. The label warns of a transient blood-pressure rise — paired with a drop in heart rate — and contraindicates the drug in uncontrolled hypertension or known cardiovascular disease [11][9]. With repeated dosing, skin, gums, and breast tissue can darken [12]. A published re-analysis argued the desire and distress effects, while statistically significant, are small [13]. The tolerability picture — what worked and what did not — is the center of this site, on PT-141 side effects.
Subcutaneous (injected just under the skin) is the approved route. The half-life is short — roughly 2.7 hours — which is why it is taken as needed rather than daily [11]. See how long PT-141 lasts, or read the full PT-141 side effects record.